Key result
Neonova TEER achieves ~93% one-year treatment success in high-risk primary MR, exceeding performance goals.
Why the study?
TEER is established for severe primary MR, but robust clinical data in Asian populations are limited.
Does the Neonova TEER system achieve treatment success compared to a performance goal in high-risk patients with symptomatic primary mitral regurgitation?
Does the Neonova TEER system achieve treatment success compared to a performance goal in high-risk patients with symptomatic primary mitral regurgitation?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The [two]-year Neonova trial demonstrates the feasibility and safety of this novel device in a carefully selected primary-MR cohort… Ultimately, integration of a multidisciplinary heart-team approach in treating patients with severe MR remains the cornerstone of delivering high-quality transcathe...”
The novel Neonova TEER system demonstrated high 1-year treatment success (92.68%) that exceeded performance goals in high-risk Chinese patients with primary mitral regurgitation.
BACKGROUND: Transcatheter edge-to-edge repair (TEER) is established for severe primary mitral regurgitation (MR), but robust clinical data in Asian populations are limited. OBJECTIVES: This study aimed to evaluate the safety and efficacy of the novel Neonova TEER system in high-risk Chinese patients with symptomatic, moderate-to-severe or severe primary MR. METHODS: This prospective, multicenter, single-arm, performance-goal pivotal trial enrolled 123 patients from 23 Chinese centers (April 2022 to March 2024). Eligible patients had symptomatic primary MR (≥3+) and high surgical risk. The primary efficacy endpoint was treatment success at 1 year (freedom from mortality, mitral valve surgery, and MR >2+) compared with a 60% performance goal. Follow-up extended to 2 years. RESULTS: Event-free survival at 1 year was 92.68%, exceeding the target value, and remained 84.55% at 2 years. The proportion of patients with MR ≤2+ was 96.61% at 1 year and 95.41% at 2 years. Immediate procedural success was 98.37%. The proportion of patients in NYHA functional class I/II improved from 0% at baseline to 94.92% at 1 year, sustained at 92.52% at 2 years. Significant left ventricular reverse remodeling occurred. The composite major adverse event rate was 8.13% at 1 year, with all-cause mortality at 2.44%. All-cause mortality at 2-year follow-up was only 4.07%. CONCLUSIONS: The novel TEER system demonstrates excellent safety and efficacy for high-risk primary MR patients, achieving high event-free survival and sustained clinical and echocardiographic improvements through 2 years. It offers a reliable, minimally invasive alternative to conventional surgery.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied Symptomatic, moderate-to-severe or severe primary mitral regurgitation (n=123). Neonova TEER system vs. 60% performance goal was evaluated on Treatment success at 1 year (freedom from mortality, mitral valve surgery, and MR >2+). The Neonova TEER system achieved a 92.68% 1-year treatment success rate (freedom from mortality, surgery, and MR >2+) in high-risk primary MR patients, exceeding the 60% performance goal.
Synapse has enriched 10 related papers. Consider them for comparative context: